Invivyd, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 9, 2023. Financial amounts below are in millions of dollars unless otherwise noted. Invivyd is a clinical-stage biopharmaceutical company developing antibody therapies, initially targeting COVID-19. It had generated no revenue through the reporting period.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $25.6 | $30.1 | $96.4 | $159.3 |
| Acquired in-process R&D expense | $4.6 | $4.0 | $5.6 | $4.0 |
| Selling, general and administrative expense | $12.9 | $13.2 | $34.0 | $36.5 |
| Total operating expenses / operating loss | $43.1 | $47.3 | $136.0 | $199.8 |
| Other income | $3.6 | $2.2 | $11.0 | $3.1 |
| Net loss | $39.4 | $45.1 | $125.0 | $196.7 |
| Net loss per share, basic and diluted | $0.36 | $0.42 | $1.14 | $1.82 |
At September 30, 2023, cash and cash equivalents were $181.8 million and marketable securities were $83.1 million, totaling approximately $264.9 million. Current assets were $270.1 million and current liabilities $26.8 million. Total liabilities were $28.4 million, including operating lease liabilities; the filing reports no financial borrowings. Nine-month operating cash use was $113.9 million, compared with $172.6 million in 2022. Investing activities provided $202.8 million, mainly from marketable-security maturities; financing activities provided $0.9 million. No operating margin or gross margin is meaningful given the absence of revenue.
Material changes versus prior comparable periods
- Q3 net loss narrowed by $5.6 million year over year; nine-month net loss narrowed by $71.8 million. The nine-month decrease in R&D expense was chiefly due to lower adintrevimab manufacturing and clinical costs, partly offset by VYD222 development and manufacturing spending.
- VYD222 direct external R&D expense was $52.7 million for the first nine months of 2023, while adintrevimab expense fell to $3.4 million from $107.0 million. The company prioritized VYD222 over NVD200.
- Other income rose, reflecting interest earned and accretion of discounts on marketable securities. The increase helped reduce reported net loss but did not represent product revenue.
- Cash and marketable securities declined from approximately $372.0 million at December 31, 2022 to $264.9 million at September 30, 2023, despite cash and cash equivalents increasing during the nine-month period as securities matured.
Outlook, risks and unusual items
- Management estimated existing cash, cash equivalents and marketable securities would fund operating expenses and capital expenditures for at least 12 months from issuance of the interim financial statements. It expects continued operating losses and may seek equity, grants or other funding; additional financing may dilute shareholders or be unavailable on acceptable terms.
- VYD222 Phase 3 CANOPY trial began dosing in September. The filing, including its subsequent-event disclosure, reports enrollment completed in November at approximately 750 participants. Initial primary-endpoint data were expected by late 2023 or early Q1 2024. The company aimed to seek FDA emergency use authorization as soon as practicable and was preparing for a potential U.S. launch in 2024, if authorized. These expectations are not guarantees.
- The company reported general alignment with FDA on a potential immunobridging development pathway; authorization remains subject to trial results, regulatory review and other requirements. Evolving SARS-CoV-2 variants, vaccine and treatment uptake, trial execution, manufacturing, supply chains and market acceptance could affect prospects.
- New noncancelable VYD222 manufacturing commitments totaled $50.9 million: $10.4 million for resin, $5.7 million for materials and $34.8 million for commercial drug-substance batches. These are future commitments, not all reported as current-period expense.
- Adimab-related items include a $3.2 million Q3 milestone expense and a $3.2 million milestone payment made in October. Adimab is a principal stockholder; $5.8 million was due to Adimab at period-end. Potential further milestone and royalty obligations depend on specified events and future sales.
- A securities class action alleges misleading statements concerning ADG20’s effectiveness against Omicron. The company intends to defend the case but stated the outcome and potential materiality could not yet be assessed.
- The company reported no material changes to the risk factors in its 2022 Form 10-K. Management concluded disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- CANOPY trial data timing and results, including the immunobridging endpoint and safety findings, and any subsequent FDA feedback or EUA decision.
- Actual cash burn, remaining liquidity and financing needs relative to management’s stated 12-month runway and the $50.9 million manufacturing commitments.
- Manufacturing readiness, product supply costs and commercial strategy for a potential VYD222 launch.
- Changes in circulating variants and the resulting relevance of VYD222’s neutralization data, clinical design and potential market demand.
- Developments in the securities lawsuit, Adimab-related obligations and potential dilution from equity awards and warrants; the filing lists 6.8 million PHP warrants outstanding.